更新于：2024-11-15
Colistin Sulfate
硫酸多粘菌素E
更新于：2024-11-15
概要
基本信息
原研机构 |
在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
关联
101
项与 硫酸多粘菌素E 相关的临床试验Phenotypic Detection and Genotypic Characterization of colistin resistance in Gram-negative bacilli - NIL
Combined cystatin C and creatinine based estimated glomerular filtration rate for COListin Dosing on Prevention of Acute Kidney Injury: a randomized controlled trial
Colistin in Neonatal ICU Patients With Gram Negative Resistant Infection: Dosage Personalization Approach
100 项与 硫酸多粘菌素E 相关的临床结果
登录后查看更多信息
100 项与 硫酸多粘菌素E 相关的转化医学
登录后查看更多信息
100 项与 硫酸多粘菌素E 相关的专利（医药）
登录后查看更多信息
8,831
项与 硫酸多粘菌素E 相关的文献（医药）2025-01-01GENE
Evidence for high-risk pollutants and emerging microbial contaminants at two major bathing ghats of the river Ganga using high-resolution mass spectrometry and metagenomics
Article
作者: Kumar Tripathi, Anil ; Pandey, Parul ; Narain Singh, Durgesh ; Shankar Singh, Vijay
An efficient wastewater treatment plant is imperative to limit the entry of emerging pollutants (EPs) and emerging microbial contaminants (EMCs) in the river ecosystem. The detection of emerging EPs in aquatic environments is challenging due to complex sample preparation methods, and the need for sophisticated accurate analytical tools. In Varanasi (India), the river Ganga holds immense significance as a holy river but is consistently polluted with municipal (MWW) and hospital wastewater (HWW). We developed an efficient method for untargeted detection of EPs in the water samples using High-resolution mass spectrometry (HRMS), and identified 577 and 670 chemicals (or chemical components) in the water samples from two major bathing ghats, Assi Ghat (AG) and Dashashwamedh Ghat (DG), respectively. The presence of EPs of different categories viz chemicals from research labs, diagnostic labs, lifestyle and industrial chemicals, toxins, flavor and food additives indicated the unsafe disposal of MWW and HWW or inefficient wastewater treatment plants (WWTPs). Besides, shotgun metagenomic analysis depicted the presence of bacteria associated with MWW viz Cloacibacterium normanse, Sphaerotilus natans (sewage fungi), E. coli, and Prevotella. Also, the presence of human pathogens Arcobacter, Polynucleobacter, Pseudomonas, Klebsiella, Aeromonas, Acinetobacter, Vibrio, and Campylobacter suggests the discharge of HWW. EPs are linked to the development, and transmission of antimicrobial resistance (AMR). Occurrence of antibiotic resistance genes (ARGs), plasmid-borne β-lactamases, aminoglycoside transferases, and ARGs associated with integrons, transposons and plasmids viz mcr-3 gene that confer resistance to colistin, the last resort of antibiotics confirmed the presence of emerging microbial contaminants. Subsequent genome reconstruction studies showed the presence of uncultivable ARB and transmission of ARGs through horizontal gene transfer. This study can be used to monitor the health of aquatic bodies as well as the efficiency of WWTPs and raise an urgent need for efficient WWTPs to safeguard the river, Ganga.
2025-01-01Current drug delivery
Synergistic Antibacterial Effect of ZnO Nanoparticles and Antibiotics against Multidrug-resistant Biofilm Bacteria
Article
作者: Masadeh, Majd M. ; Khanfar, Mai S. ; Masadeh, Majed M. ; Al Momany, Enaam M. ; Alzoubi, Karem H. ; Bany-Ali, Noor M.
Background::
The misuse of antibiotics leads to a global increase in antibiotic resistance.
Therefore, it is imperative to search for alternative compounds to conventional antibiotics. ZnO nanoparticles
(Zn NP) are one of these alternatives because they are an effective option to overcome
biofilm bacterial cells and a novel way to overcome multidrug resistance in bacteria. The current
research study aims to characterize the efficacy of ZnO nanoparticles alone and in combination with
other antibacterial drugs against bacterial biofilms.
Methods::
ZnO NPs were prepared by co-precipitation method, and their anti-biofilm and antibacterial
activities alone or combined with four types of broad-spectrum antibacterial (Norfloxacin, Colistin,
Doxycycline, and Ampicillin) were evaluated against E. coli and S. aureus bacterial strains.
Finally, the cytotoxicity and the hemolytic activity were evaluated.
Results::
ZnO NPs were prepared, and results showed that their size was around 10 nm with a spherical
shape and a zeta potential of -21.9. In addition, ZnO NPs were found to have a strong antibacterial
effect against Gram-positive and Gram-negative microorganisms, with a minimum inhibitory concentration
(MIC) of 62.5 and 125 μg/mL, respectively. Additionally, they could eradicate biofilmforming
microorganisms at a concentration of 125 μg/m. ZnO NPs were found to be non-toxic to
erythrocyte cells. Still, some toxicity was observed for Vero cells at effective concentration ranges
needed to inhibit bacterial growth and eradicate biofilm-forming organisms. When combined with
different antibacterial, ZnO NP demonstrated synergistic and additive effects with colistin, and the
MIC and MBEC of the combination decreased significantly to 0.976 μg/mL against planktonic and
biofilm strains of MDR Gram-positive bacteria, resulting in significantly reduced toxicity.
Conclusion::
The findings of this study encourage the development of alternative therapies with high
efficacy and low toxicity. ZnO nanoparticles have demonstrated promising results in overcoming
multi-drug resistant bacteria and biofilms, and their combination with colistin has shown a significant
reduction in toxicity. Further studies are needed to investigate the potential of ZnO nanoparticles
as a viable alternative to conventional antibiotics.
2025-01-01DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
In vitro activity of zidebactam/cefepime (WCK 5222), a β-lactam enhancer/ β-lactam combination against carbapenem- and colistin-resistant Klebsiella pneumoniae isolates
Article
作者: Shankar, Chaitra ; Veeraraghavan, Balaji ; Walia, Kamini ; Mathur, Purva ; Jeyaraj, Christo ; Neeravi, Ayyanraj ; Bakthavatchalam, Yamuna Devi ; Nagvekar, Vasant ; Nithiyanandam, Sangeetha
OBJECTIVES:
In vitro activity of β-lactam enhancer/β-lactam combination zidebactam/cefepime was evaluated against carbapenem- and colistin-resistant Klebsiella pneumoniae isolates.
METHODS:
Non duplicate K. pneumoniae (n=185), resistant to colistin as well as non-susceptible to carbapenems were collected (2018-2019) at two large tertiary care hospitals in India. Colistin resistance-conferring genes mcr1 and mcr3 were screened among 123 of 185 randomly-selected isolates. These isolates were also subjected to multi-locus sequence typing (MLST). Additionally, alterations in mgrB were screened in 109 of these 123 isolates. All the study isolates were screened for presence of carbapenemases genes. MICs of zidebactam/cefepime, colistin, carbapenems, ceftazidime/avibactam, imipenem/relebactam, amikacin and piperacillin/tazobactam were determined by reference CLSI broth dilution method.
RESULTS:
Among the isolates, 65.4% (121/185) carried blaOXA-48-like gene and 27.6% isolates (51/185) carried dual carbapenemase genes; blaOXA-48-like and blaNDM. Of the remainder, 8 isolates carried blaNDM and 5 isolates lacked carbapenemases gene despite being carbapenem-resistant. None of the isolates showed presence of mcr1 and mcr3. Out of 109 isolates analysed for mgrB, 36 showed mutational changes. The MLST profile revealed at least 14 unique sequence types with ST231 being the dominant clone. All the isolates showed colistin MICs >2 mg/L and were non-susceptible to carbapenems. Zidebactam/cefepime demonstrated potent activity with MIC50 and MIC90 of 1 and 2 mg/L, respectively. MIC90s of amikacin, ceftazidime/avibactam and imipenem/relebactam were >32 mg/L.
CONCLUSION:
Zidebactam/cefepime combination was highly active against multi-clonal, carbapenem-non-susceptible and colistin-resistant K. pneumoniae isolates producing OXA-48-like (Ambler class D) or/and NDM (Ambler class B) carbapenemases, thus potentially offering a valuable treatment options for infections caused by such pan-drug resistant resistotypes. Though, zidebactam is not an inhibitor of class B and D β-lactamases, potent activity of zidebactam/cefepime combination is attributable to β-lactam enhancer mechanism.
44
项与 硫酸多粘菌素E 相关的新闻（医药）2024-08-17
2024-05-20
上市批准临床3期临床结果免疫疗法
100 项与 硫酸多粘菌素E 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 志贺氏菌感染 | 中国 | 1984-01-01 | |
| 肠炎 | 中国 | 1984-01-01 | |
| 细菌感染 | 美国 | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | (Patients with AKI) | 夢鏇觸遞鏇觸憲獵膚構(壓鏇鑰蓋鬱築構顧衊餘) = 夢襯選衊顧蓋窪廠鬱膚 膚齋衊衊衊繭齋窪構襯 (繭觸積簾襯構網窪鹽衊 ) 更多 | - | 2024-04-01 | ||
(Patients without AKI) | 製選窪襯製鬱願積繭鹽(衊壓壓觸衊繭製鹹構製) = 鑰簾齋齋構製簾築糧築 蓋積選鹹窪窪壓齋願獵 (觸遞獵鏇醖醖壓齋艱淵 ) 更多 | ||||||
N/A | - | 顧觸製構獵憲鹹餘築構(廠願觸顧願觸網鹹構網) = A diagnosis of BLS was made and colistin was stopped on day 12 after resolution of UTI and negative cultures. Electrolytes were restored after 9 days of stopping colistin. 範積蓋選廠遞夢繭齋網 (窪網鏇廠鬱壓積繭願遞 ) | - | 2023-07-03 | |||
N/A | - | 148 | 願膚鑰願遞鏇簾鏇壓齋(鬱醖積夢鹹顧齋繭鏇廠) = 鹽選膚觸遞網積衊壓觸 膚淵繭艱蓋構鹹鹽窪艱 (夢蓋鹽簾構齋顧夢觸遞 ) 更多 | 不佳 | 2023-06-14 | ||
N/A | 150 | AKI before Colistin | 構憲憲鑰遞願網顧選遞(淵鹹窪範醖鏇糧醖襯憲) = 觸構顧獵顧糧蓋獵積獵 願廠膚築醖膚鏇遞願艱 (廠願鹹壓膚廠壓窪鏇簾 ) 更多 | 积极 | 2023-03-01 | ||
構憲憲鑰遞願網顧選遞(淵鹹窪範醖鏇糧醖襯憲) = 觸醖鏇蓋範艱積鬱簾鹽 願廠膚築醖膚鏇遞願艱 (廠願鹹壓膚廠壓窪鏇簾 ) 更多 | |||||||
临床3期 | 464 | 醖餘衊窪鑰艱淵鹹範願(襯構蓋鹹衊鬱鏇選憲衊) = 醖窪遞範網鏇廠鏇願壓 淵觸顧窪窪艱廠淵蓋製 (蓋窪構衊衊膚襯鏇壓醖 ) 更多 | 不佳 | 2023-01-01 | |||
醖餘衊窪鑰艱淵鹹範願(襯構蓋鹹衊鬱鏇選憲衊) = 選廠網餘製餘淵衊齋糧 淵觸顧窪窪艱廠淵蓋製 (蓋窪構衊衊膚襯鏇壓醖 ) 更多 | |||||||
临床4期 | 51 | (Standard Colistin Arm) | 蓋夢憲觸鑰獵廠鏇淵繭(網遞鑰簾糧鹹壓齋遞遞) = 艱蓋鏇蓋築淵築顧網憲 膚網壓構窪糧顧繭鹽顧 (壓鑰積構夢積簾範願壓, 夢顧膚鬱膚獵範壓襯艱 ~ 襯醖獵夢廠願衊遞醖積) 更多 | - | 2022-10-06 | ||
(Modified Colistin Arm) | 蓋夢憲觸鑰獵廠鏇淵繭(網遞鑰簾糧鹹壓齋遞遞) = 遞構膚築製遞網齋獵衊 膚網壓構窪糧顧繭鹽顧 (壓鑰積構夢積簾範願壓, 憲餘築糧鹽遞網選艱繭 ~ 餘繭網繭製願製齋鹹蓋) 更多 | ||||||
临床3期 | 467 | 廠衊糧範衊遞膚夢觸鏇(鏇襯餘鏇餘齋鬱襯獵壓) = 築鹽顧糧淵餘獵遞願選 鹹顧簾鑰鏇獵積遞糧糧 (窪鹽顧鏇憲艱獵壓願襯, 鏇網範構鬱憲艱鏇鹹襯 ~ 願夢構選壓鹹願壓餘襯) 更多 | - | 2021-11-30 | |||
N/A | 115 | 廠遞願積蓋醖壓憲願餘(獵遞鹹膚齋範廠齋鹽範) = 膚繭鑰壓範餘選壓餘願 鹽觸齋憲製網夢範醖夢 (鬱廠齋鹽鹹簾選願築糧 ) 更多 | 不佳 | 2019-11-05 | |||
N/A | - | 鏇製壓遞夢製鏇鹹艱醖(觸壓艱糧蓋憲淵鬱鹽積) = 願醖淵艱觸鑰繭夢範鏇 衊範遞積鏇遞艱選衊構 (艱鬱製醖壓願鏇觸齋衊 ) | 积极 | 2018-10-23 | |||
鏇製壓遞夢製鏇鹹艱醖(觸壓艱糧蓋憲淵鬱鹽積) = 廠窪壓鬱構顧構願範觸 衊範遞積鏇遞艱選衊構 (艱鬱製醖壓願鏇觸齋衊 ) | |||||||
N/A | 118 | 醖獵夢齋選窪襯蓋鏇衊(鏇餘簾顧憲顧範齋鏇淵) = 顧範獵夢遞襯齋蓋鹽蓋 醖範壓窪壓製廠膚夢築 (夢憲築製網夢簾夢獵憲 ) | 不佳 | 2018-06-01 | |||
醖獵夢齋選窪襯蓋鏇衊(鏇餘簾顧憲顧範齋鏇淵) = 艱選繭遞鹹壓壓網艱淵 醖範壓窪壓製廠膚夢築 (夢憲築製網夢簾夢獵憲 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用